Olu vavanyo lubona ama-autoantibodies anceda ukuqinisekisa ukuxilongwa
Uvavanyo lwe-anti-CCP lisetyenziselwa ukufumana ii-autoantibodies kunye ncedisi ukuhlula phakathi kwesifo se-rheumatoid and other types of inflammatory arthritis . I-antibody ye-peptide ye-peptide ye-peptide (CCP) i-cyclic citrullinated (CPP) i-autoantibody ngokumelene nama-protein ase-citrullinated (ACPA) kwaye ilinganiswa ngolu vavanyo.
Uvavanyo luba nobukhulu obuphezulu malunga nesifo se- rheumatoid arthritis , esibikwa phakathi kwama-50 no-75 ekhulwini.
Kwakhona kunendawo ephezulu kakhulu kwi-rheumatoid arthritis malunga neepesenti ezingama-90. Ubume bakhe obuphezulu kukuba kutheni uvavanyo lwe-anti-CCP lube yinxalenye ebalulekileyo yenkqubo yokuxilonga ye-rheumatoid arthritis.
Ixabiso lokuThengwa koVavanyo lwe-Anti-CCP kunye nePrognostic Value
Ngaphandle kokuncedisa ukuhlula phakathi kweentlobo ezivuthayo zesifo se-arthritis , uvavanyo lwe-anti-CCP luxabisekileyo kakhulu ekufumaneni abantu abasebenzisa i- seronegative kwi- rheumatoid factor . Uvavanyo oluchasene neCCP aluyixabiso kuphela lokuhlola (ukucacisa ukuba yeyiphi imeko enayo), nayo inenani lentengiso (ukuchaza kwangaphambili imeko yeemeko zakho).
Ukuba i-anti-CCP ikhona kwizinga eliphakamileyo ukuya kumgangatho ophakamileyo, akusizi nje kuphela ukuqinisekisa ukuxilongwa, kubonisa ukuba kunokuba ibe yinkqubo ebhubhisayo yesifo esichengileyo, njengomonakalo ohlanganyelweyo. Amanqanaba aphantsi a-antibody awaxeli okanye athetha.
Ngokuqhelekileyo, uvavanyo lwe-anti-CCP luyalwa kunye ne-test ye-rheumatoid test, kuba akukho vavanyo lodwa lungaqinisekisa ngokuqinisekileyo ukuxilongwa kwe-rheumatoid arthritis.
Ngokwe-rheumatologist uScott J. Zashin, "Nangona i-rheumatoid factor in common people in a rheumatoid arthritis, kukho abantu abaneempembelelo ze-rheumatoid abangenayo i-rheumatoid arthritis. i-ACPA.
Kwakhona, ukuba umntu ungeyinto engathinteki kwi-rheumatoid factor, ababanako ukuba babe ne-ACPA. "
Ukuchonga ama-Autoantibodies
Ukubaluleka kokuchonga ii-autoantibodies kwizifo ze-rheumatic bekuye kwaqatshelwa iminyaka emininzi, kodwa ukuchonga abo babecala ngokubhekiselele kwiinkcukacha ezithile kunye nobubele kuthatha ixesha. Kukho izizukulwana ezintathu zovavanyo lwe-anti-CCP. Ngesizukulwana ngasinye sokuvavanya ubuninzi kunye nobuzwe buphuculwe.
Ngokutsho kwe "Kelley's Bookbook yeRheumatology," abangaphezu kwama-90 ekhulwini abantu abane- arthritis engaxhatshazwayo abavavanya kakuhle kwi-anti-CCP bakhula i-rheumatoid arthritis kwiminyaka emithathu. Kuphela malunga neepesenti ezingama-25 zabangenayo i-arthritis engaxhatshazwanga abavavanya i-anti-CCP yokuvelisa i-rheumatoid arthritis.
I-Autoantibodies iyakwazi ukubonakala phambi kokuqala kweekliniki zezifo ezithile ezizimeleyo, kuquka i-rheumatoid arthritis. I-Autoantibodies ingabangela ukuqala kwesifo se-rheumatoid arthritis iminyaka emibili ukuya kwimithandathu, ngokutsho kwe "Kelley's Bookbook yeRheumatology." Ingxelo, i-anti-CCP elandelelweyo ephambi kokuxilongwa kwe-rheumatoid arthritis iphindwe kabili njengento ebonakalayo ye-rheumatoid eyandulela ukuxilongwa.
Nangona i-rheumatoid factor ihlala ihlala ihlala ikhona, ubukho be-anti-CCP buyahlukahluka kwizigulane ze-rheumatoid arthritis-zinyamalale kwezinye iimeko.
Ubalulekileyo be-Anti-CCP
Abaphandi baqhubeka bejonge oko kwenzekayo emzimbeni ukuvelisa iamolekyuli (i-antigens) ezenza ukuveliswa kwezi antibodies anti-CCP. Zibizwa ngokuba yi-autoantigens kuba ziveliswa ngokuphuka kwamalungu ngaphakathi komzimba kunokuba zivela ngaphandle komzimba. I-Peptidylarginine deiminase (PAD) i-enzymes, eyenza ukuguqulwa kwe-peptidylarginine ibe yi-peptidylcitrulline, inendima ebalulekileyo ekuveliseni i-autoantigens kwi-rheumatoid arthritis.
Kwakhona uphando olongezelelweyo lufunekayo ukucacisa oko kubangela ukuba isigaba sokuqala sesifo se-rheumatoid arthritis sitshintshele kwi-symptomatic, full-fledged process process.
Nangona i-anti-CCP ichanekile kakhulu kwi-arthritis ye-rheumatoid, iziphumo ezintle ziyakwenzeka nezinye izifo zemizimba yesifo se-rheumatic, isifo sofuba kunye nesifo esingapheliyo. Ama-antibodies anti-CCP abiwe kwi- systemic lupus erythematosus kunye nesifo se-Sjogren esisisiseko, ngokuqhelekileyo xa i-arthritis ekhoyo ikhona. Kuye kwafunyanwa kwiipesenti ezingama-16 zabantu abane- arthritis ye-psoriatic- ngokugqithiseleyo kunye ne-polythritis. Ngamanye amaxesha, ihamba ne-psoriasis enamandla ngaphandle kwe-arthritis.
> Imithombo:
> Cush JJ, Kavanaugh A, Weinblatt ME. I-Rheumatoid Arthritis: I-Early diagnosis and Treatment . I-West Islip, NY: UQhagamshelwano loBugcisa; 2010.
> Firestein GS, uKelley WN. I-Kelleys Bookbook yeRheumatology . Philadelphia, PA: Elsevier / Saunders; 2013.
> Taylor PC, i-Maini RN. AbaMakethi beBioologic kwi-Diagnosis and Assessment ye-Rheumatoid Arthritis. Isemgangathweno. https://www.uptodate.com/contents/biologic-markers-in-the-diagnosis-andessassment-of-rheumatoid-arthritis.